T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study

F. Schettini, B. Conte, G. Buono, P. De Placido, S. Parola, G. Griguolo, A. Fabi, C. Bighin, F. Riccardi, D. Cianniello, M. De Laurentiis, F. Puglisi, G. Pelizzari, M. Bonotto, S. Russo, A. Frassoldati, A. Pazzola, F. Montemurro, M. Lambertini, V. GuarneriF. Cognetti, M. Locci, D. Generali, P. Conte, S. De Placido, M. Giuliano, G. Arpino, L. Del Mastro

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study'. Together they form a unique fingerprint.

Medicine & Life Sciences